Clinical Trial Update: Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanoma has completed; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: High Risk Stage III Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2014-08-19